Here's Why.
| Mechanisms of action by which addressing each risk factor can potentially reduce dementia risk. (WHO) |
Dementia research has reached a profound turning point.
Alzheimer's
disease was once considered 'untreatable', but that is not the universal rule
any longer, according to this year's World Alzheimer Report.
In the past five years alone, novel drugs have been shown to
modestly slow decline in early Alzheimer's, while growing evidence suggests
some dementia cases could potentially be delayed or prevented through risk
reduction.
Today, hundreds of clinical
trials worldwide are now investigating possible medicines, new diagnostic
options, and lifestyle interventions to identify, treat, or delay cognitive
decline.
The possibility of a cure is still far away, but it
"feels like a more palpable prospect than ever before," according to
the 2026 World Alzheimer Report, coauthored by Alzheimer's Disease
International (ADI) and leading health journalist Paul Gallagher.
"After decades during which dementia was widely
regarded as an inevitable consequence of old age and neurodegeneration with few
therapeutic options beyond symptom management, research has entered an era of
unprecedented activity," reads
the report.
"Alzheimer's disease is no longer universally described
as untreatable; instead, it is increasingly viewed as a condition for which
earlier diagnosis, better understanding of disease biology, and a wider range
of interventions may collectively improve outcomes."
ADI
calls itself the 'global voice of dementia'.
It is a worldwide federation of dementia associations in official relations
with the World Health Organization (WHO).





.webp)







.webp)

